189 related articles for article (PubMed ID: 7666230)
21. U74389G prevents vasospasm after subarachnoid hemorrhage in dogs.
Macdonald RL; Bassiouny M; Johns L; Sajdak M; Marton LS; Weir BK; Hall ED; Andrus PK
Neurosurgery; 1998 Jun; 42(6):1339-45; discussion 1345-6. PubMed ID: 9632194
[TBL] [Abstract][Full Text] [Related]
22. A dosage study of the effect of the 21-aminosteroid U74006F on chronic cerebral vasospasm in a primate model.
Kanamaru K; Weir BK; Findlay JM; Grace M; Macdonald RL
Neurosurgery; 1990 Jul; 27(1):29-38. PubMed ID: 2377279
[TBL] [Abstract][Full Text] [Related]
23. Effect of intracarotid nitric oxide on primate cerebral vasospasm after subarachnoid hemorrhage.
Afshar JK; Pluta RM; Boock RJ; Thompson BG; Oldfield EH
J Neurosurg; 1995 Jul; 83(1):118-22. PubMed ID: 7782826
[TBL] [Abstract][Full Text] [Related]
24. Intraarterial infusion of papaverine in experimental cerebral vasospasm.
Fujiwara N; Honjo Y; Ohkawa M; Tanabe M; Irie K; Nagao S; Takashima H; Satoh K; Kojima K
AJNR Am J Neuroradiol; 1997 Feb; 18(2):255-62. PubMed ID: 9111660
[TBL] [Abstract][Full Text] [Related]
25. BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection.
Clozel M; Watanabe H
Life Sci; 1993; 52(9):825-34. PubMed ID: 8437512
[TBL] [Abstract][Full Text] [Related]
26. The effect of timing of clot removal on chronic vasospasm in a primate model.
Handa Y; Weir BK; Nosko M; Mosewich R; Tsuji T; Grace M
J Neurosurg; 1987 Oct; 67(4):558-64. PubMed ID: 3655894
[TBL] [Abstract][Full Text] [Related]
27. Role of ferrous iron chelator 2,2'-dipyridyl in preventing delayed vasospasm in a primate model of subarachnoid hemorrhage.
Horky LL; Pluta RM; Boock RJ; Oldfield EH
J Neurosurg; 1998 Feb; 88(2):298-303. PubMed ID: 9452239
[TBL] [Abstract][Full Text] [Related]
28. Antisense preproendothelin-oligoDNA therapy for vasospasm in a canine model of subarachnoid hemorrhage.
Ohkuma H; Parney I; Megyesi J; Ghahary A; Findlay JM
J Neurosurg; 1999 Jun; 90(6):1105-14. PubMed ID: 10350259
[TBL] [Abstract][Full Text] [Related]
29. A randomized placebo-controlled double-blind trial of nimodipine after SAH in monkeys. Part 1: Clinical and radiological findings.
Espinosa F; Weir B; Overton T; Castor W; Grace M; Boisvert D
J Neurosurg; 1984 Jun; 60(6):1167-75. PubMed ID: 6726360
[TBL] [Abstract][Full Text] [Related]
30. Is vasospasm related to proliferative arteriopathy?
Pluta RM; Zauner A; Morgan JK; Muraszko KM; Oldfield EH
J Neurosurg; 1992 Nov; 77(5):740-8. PubMed ID: 1403117
[TBL] [Abstract][Full Text] [Related]
31. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm.
Shigeno T; Clozel M; Sakai S; Saito A; Goto K
Neurosurgery; 1995 Jul; 37(1):87-90; discussion 90-1. PubMed ID: 8587696
[TBL] [Abstract][Full Text] [Related]
32. [Effect of nimodipine on vasospasm of cortical arteries. Experimental study].
Tadie M
Neurochirurgie; 1992; 38(3):134-7. PubMed ID: 1461329
[TBL] [Abstract][Full Text] [Related]
33. Posttraumatic cerebral arterial spasm: transcranial Doppler ultrasound, cerebral blood flow, and angiographic findings.
Martin NA; Doberstein C; Zane C; Caron MJ; Thomas K; Becker DP
J Neurosurg; 1992 Oct; 77(4):575-83. PubMed ID: 1527618
[TBL] [Abstract][Full Text] [Related]
34. Effects of tirilazad mesylate on vasospasm and phospholipid hydroperoxides in a primate model of subarachnoid hemorrhage.
Suzuki H; Kanamaru K; Kuroki M; Sun H; Waga S; Miyazawa T
Stroke; 1999 Feb; 30(2):450-5; discussion 455-6. PubMed ID: 9933286
[TBL] [Abstract][Full Text] [Related]
35. Development of calcitonin gene-related peptide slow-release tablet implanted in CSF space for prevention of cerebral vasospasm after experimental subarachnoid haemorrhage.
Ahmad I; Imaizumi S; Shimizu H; Kaminuma T; Ochiai N; Tajima M; Yoshimoto T
Acta Neurochir (Wien); 1996; 138(10):1230-40. PubMed ID: 8955444
[TBL] [Abstract][Full Text] [Related]
36. Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists.
Zuccarello M; Soattin GB; Lewis AI; Breu V; Hallak H; Rapoport RM
J Neurosurg; 1996 Mar; 84(3):503-7. PubMed ID: 8609565
[TBL] [Abstract][Full Text] [Related]
37. Prevention of delayed vasospasm by an endothelin ETA receptor antagonist, BQ-123: change of ETA receptor mRNA expression in a canine subarachnoid hemorrhage model.
Itoh S; Sasaki T; Asai A; Kuchino Y
J Neurosurg; 1994 Nov; 81(5):759-64. PubMed ID: 7931624
[TBL] [Abstract][Full Text] [Related]
38. Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin, and methemoglobin after subarachnoid hemorrhage.
Pluta RM; Afshar JK; Boock RJ; Oldfield EH
J Neurosurg; 1998 Mar; 88(3):557-61. PubMed ID: 9488312
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of nicardipine prolonged-release pellet on cerebral vasospasm in dogs].
Kawashima A; Kasuya H; Shiokawa K; Miyajima M; Izawa M; Takakura K
No Shinkei Geka; 1998 Jan; 26(1):37-43. PubMed ID: 9488990
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.
Findlay JM; Kassell NF; Weir BK; Haley EC; Kongable G; Germanson T; Truskowski L; Alves WM; Holness RO; Knuckey NW
Neurosurgery; 1995 Jul; 37(1):168-76; discussion 177-8. PubMed ID: 8587685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
